132 related articles for article (PubMed ID: 36733175)
1. [Total Pancreatectomy for Remnant Pancreatic Cancer with Positive Washing Cytology after Conversion to Negative Cytology Following Gemcitabine plus Nab-Paclitaxel Therapy-A Case Report].
Nakajima K; Maruyama T; Aono T; Suzuki S; Kaneko K; Sato T; Okada T; Muto I; Hasegawa M; Muneoka Y; Tajima Y; Ichikawa H; Shimada Y; Sakata J; Wakai T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1681-1683. PubMed ID: 36733175
[TBL] [Abstract][Full Text] [Related]
2. [Conversion Surgery for Pancreatic Head Cancer with Peritoneal Dissemination Following Chemotherapy for Two Years - A Case Report].
Hatsuzawa Y; Mizuma M; Motoi F; Hata T; Iseki M; Takadate T; Ohtsuka H; Sakata N; Morikawa T; Nakagawa K; Hayashi H; Naitoh T; Kanno A; Shimosegawa T; Unno M
Gan To Kagaku Ryoho; 2018 Feb; 45(2):347-349. PubMed ID: 29483443
[TBL] [Abstract][Full Text] [Related]
3. [Resectable Pancreatic Cancer Successfully Treated with Neoadjuvant Chemotherapy Regimen Change to Modified FOLFIRINOX-A Case Report].
Terao H; Maruyama T; Aono T; Suzuki S; Kaneko K; Sato T; Okada T; Muto I; Hasegawa M; Muneoka Y; Tajima Y; Ichikawa H; Shimada Y; Sakata J; Wakai T
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1569-1571. PubMed ID: 38303344
[TBL] [Abstract][Full Text] [Related]
4. A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Hiyoshi M; Nanashima A; Wada T; Tsuchimochi Y; Hamada T; Yano K; Imamura N; Fujii Y
Clin J Gastroenterol; 2017 Dec; 10(6):551-557. PubMed ID: 29086227
[TBL] [Abstract][Full Text] [Related]
5. [A Case of Conversion Surgery after Long-Term Chemotherapy for Pancreatic Cancer with Peritoneal Metastasis].
Enoki M; Gotoh K; Sakai K; Toshiyama R; Yanagisawa K; Kawai K; Miyo M; Takahashi Y; Hamakawa T; Doi T; Takeno A; Katoh T; Takami K; Hirao M
Gan To Kagaku Ryoho; 2023 Jan; 50(1):87-89. PubMed ID: 36759995
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
7. [Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report].
Kinoshita S; Sho M; Akahori T; Nomi T; Yamato I; Hokutoh D; Yasuda S; Nakajima Y
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1883-5. PubMed ID: 23267918
[TBL] [Abstract][Full Text] [Related]
8. GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report.
Yoshii H; Izumi H; Abe R; Tajiri T; Mukai M; Nomura E; Makuuchi H
Tokai J Exp Clin Med; 2019 Dec; 44(4):85-89. PubMed ID: 31768996
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Pathological Complete Response Following Neoadjuvant Chemotherapy with Gemcitabine plus Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer].
Ohno N; Ishida M; Ohnishi K; Sawai K; Tabata S; Deguchi M; Kitajima T; Kaizaki Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1735-1738. PubMed ID: 29394759
[TBL] [Abstract][Full Text] [Related]
11. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
[TBL] [Abstract][Full Text] [Related]
12. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M
Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].
Okazaki M; Tajima H; Ohbatake Y; Terai S; Nakanuma S; Okamoto K; Sakai S; Makino I; Kinoshita J; Nakamura K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Ohta T
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2162-2164. PubMed ID: 30692318
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
[TBL] [Abstract][Full Text] [Related]
17. [Re-resection for local recurrence in the remnant pancreas after pancreaticoduodenectomy for pancreatic cancer- a case report].
Kim C; Tono T; Kimura Y; Watanabe A; Nakamura H; Inadome J; Danno K; Kagara N; Taniguchi H; Kanoh T; Ohnishi T; Nakano Y; Monden T; Imaoka S
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2448-50. PubMed ID: 22202409
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
Ielpo B; Caruso R; Duran H; Diaz E; Fabra I; Malavé L; Ferri V; Alvarez R; Cubillo A; Plaza C; Lazzaro S; Kalivaci D; Quijano Y; Vicente E
Surg Oncol; 2017 Dec; 26(4):402-410. PubMed ID: 29113659
[TBL] [Abstract][Full Text] [Related]
19. [A Resected Case of Adenosquamous Carcinoma of Pancreas That Relapsed in Remnant Pancreas].
Miura K; Kanazawa A; Shimizu S; Murata A; Kodai S; Nishii T; Sakurai K; Tachimori A; Tamamori Y; Kubo N; Inoue T; Nishiguchi Y
Gan To Kagaku Ryoho; 2018 Mar; 45(3):524-526. PubMed ID: 29650926
[TBL] [Abstract][Full Text] [Related]
20. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
